2-[3-(1H-imidazol-1-yl)propyl]-6,7-dimethoxy-3-(2'-methoxycarbonylphenyl)-4-nitro-1-oxo-1,2-dihydroisoquinoline | 1377966-45-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-[3-(1H-imidazol-1-yl)propyl]-6,7-dimethoxy-3-(2'-methoxycarbonylphenyl)-4-nitro-1-oxo-1,2-dihydroisoquinoline
• 英文别名: Methyl 2-[2-(3-imidazol-1-ylpropyl)-6,7-dimethoxy-4-nitro-1-oxoisoquinolin-3-yl]benzoate
• CAS: 1377966-45-4
• 化学式: C₂₅H₂₄N₄O₇
• 分子量: 492.488
• InChiKey: LWWSUWNFPVVJQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  129
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-[3-(1H-imidazol-1-yl)propyl]-6,7-dimethoxy-3-(2'-methoxycarbonylphenyl)-4-nitro-1-oxo-1,2-dihydroisoquinoline 在 sodium hydrogensulfite 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 48.0h， 以64%的产率得到11-[3-(1H-imidazol-1-yl)propyl]-2,3-dimethoxydibenzo[c,h][1,5]naphthyridine-6,12(5H,11H)-dione
  参考文献：
  名称：

  Dibenzo[c,h][1,5]naphthyridinediones as Topoisomerase I Inhibitors: Design, Synthesis, and Biological Evaluation

  摘要：

  Dibenzo[c,h][1,5]naphthyridinediones were prepared via a novel synthetic pathway. The compounds were designed as topoisomerase I (Top 1) inhibitors based on the indenoisoquinoline series of drugs. The results of biological evaluation demonstrate that, unlike very closely related dibenzo[c,h][1,6]naphthyridinediones, dibenzo[c,h][1,5]naphthyridinediones retain the Top1 inhibitory activity of similarly substituted indenoisoquinolines.

  DOI：

  10.1021/jo3006039
• 作为产物：
  描述：

  2-(3'-chloropropyl)-6,7-dimethoxy-3-(2'-methoxycarbonylphenyl)-1-oxo-1,2-dihydroisoquinoline 在 硝酸 、 potassium carbonate 、 溶剂黄146 、 sodium iodide 作用下， 以 1,4-二氧六环 、 乙酸乙酯 、 乙腈 为溶剂， 反应 38.0h， 生成 2-[3-(1H-imidazol-1-yl)propyl]-6,7-dimethoxy-3-(2'-methoxycarbonylphenyl)-4-nitro-1-oxo-1,2-dihydroisoquinoline
  参考文献：
  名称：

  Dibenzo[c,h][1,5]naphthyridinediones as Topoisomerase I Inhibitors: Design, Synthesis, and Biological Evaluation

  摘要：

  Dibenzo[c,h][1,5]naphthyridinediones were prepared via a novel synthetic pathway. The compounds were designed as topoisomerase I (Top 1) inhibitors based on the indenoisoquinoline series of drugs. The results of biological evaluation demonstrate that, unlike very closely related dibenzo[c,h][1,6]naphthyridinediones, dibenzo[c,h][1,5]naphthyridinediones retain the Top1 inhibitory activity of similarly substituted indenoisoquinolines.

  DOI：

  10.1021/jo3006039